Fig. 8: Patient immune heterogeneity in low-grade gliomas and GBMs.
From: Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
a, Flow cytometry from low-grade and GBM patient tumor samples analyzed for the indicated cell types. b–d, Flow cytometry of tumors in a for Tregs, CD4+ and CD8+ lymphocytes (b), the indicated cell types as percent of CD11b+ population in low-grade and GBM tumors and IDH1 R132H mutant and IDH1 wild-type gliomas (c); note that in low-grade and GBM panel, monocytes and macrophages were combined and for Tregs, CD4+ and CD8+ lymphocytes in low-grade, GBM, IDH1 R132H mutant and IDH1 wild-type gliomas (d). Data are presented as biologically independent tumours. n = 5 and 8 low-grade and GBM, respectively. *P = 0.04, **P = 0.007 unpaired t test, two-tailed.
